---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-22-000046"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:50:19.956336+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio Q1 net loss $57.8M ($0.76/diluted); TORREY enrollment complete; cash $271.6M

## Summary
- Phase 2 TORREY study (seralutinib in PAH) completed enrollment; topline data expected Q4 2022.
- Cash, cash equivalents & marketable securities: $271.6M as of March 31, 2022; runway into first half 2024.
- Net loss of $57.8M ($0.76 per share) vs $57.6M ($0.78) in Q1 2021; R&D $42.3M, G&A $12.0M.
- GB5121 Phase 1b/2 STAR CNS study in PCNSL expected to initiate Q2 2022.
- GB7208 Phase 1 in neuroinflammatory diseases planned for H1 2023, pending TORREY results.

## SEC filing metadata
- accession: 0001728117-22-000046
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811722000046/0001728117-22-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811722000046/goss-20220510x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-22-000046
- JSON: https://secwatch.observer/filing/0001728117-22-000046.json
- Plain text: https://secwatch.observer/filing/0001728117-22-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.